JP2018524562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524562A5 JP2018524562A5 JP2017559803A JP2017559803A JP2018524562A5 JP 2018524562 A5 JP2018524562 A5 JP 2018524562A5 JP 2017559803 A JP2017559803 A JP 2017559803A JP 2017559803 A JP2017559803 A JP 2017559803A JP 2018524562 A5 JP2018524562 A5 JP 2018524562A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- protein
- activity
- amount
- fkbp5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims description 22
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims description 22
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 208000014311 Cushing syndrome Diseases 0.000 claims description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 5
- 102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 claims 39
- 238000000034 method Methods 0.000 claims 38
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims 37
- 230000000694 effects Effects 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 230000014509 gene expression Effects 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 12
- 238000005259 measurement Methods 0.000 claims 7
- 201000005255 adrenal gland hyperfunction Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 claims 2
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims 2
- 229960003248 mifepristone Drugs 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 230000010009 steroidogenesis Effects 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims 1
- 229960001690 etomidate Drugs 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- -1 leveconaconazole Chemical compound 0.000 claims 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 claims 1
- 229960004465 metyrapone Drugs 0.000 claims 1
- 229960000350 mitotane Drugs 0.000 claims 1
- 238000011349 peptide receptor radionuclide therapy Methods 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020024990A JP6893264B2 (ja) | 2015-05-18 | 2020-02-18 | クッシング症候群についての処置を診断および評価するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163130P | 2015-05-18 | 2015-05-18 | |
| US62/163,130 | 2015-05-18 | ||
| PCT/US2016/033143 WO2016187347A1 (en) | 2015-05-18 | 2016-05-18 | Methods for diagnosing and assessing treatment for cushing's syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024990A Division JP6893264B2 (ja) | 2015-05-18 | 2020-02-18 | クッシング症候群についての処置を診断および評価するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524562A JP2018524562A (ja) | 2018-08-30 |
| JP2018524562A5 true JP2018524562A5 (enExample) | 2020-07-27 |
| JP6755264B2 JP6755264B2 (ja) | 2020-09-16 |
Family
ID=57320595
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559803A Active JP6755264B2 (ja) | 2015-05-18 | 2016-05-18 | クッシング症候群についての処置を診断および評価するための方法 |
| JP2020024990A Active JP6893264B2 (ja) | 2015-05-18 | 2020-02-18 | クッシング症候群についての処置を診断および評価するための方法 |
| JP2020145512A Pending JP2020195401A (ja) | 2015-05-18 | 2020-08-31 | クッシング症候群についての処置を診断および評価するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024990A Active JP6893264B2 (ja) | 2015-05-18 | 2020-02-18 | クッシング症候群についての処置を診断および評価するための方法 |
| JP2020145512A Pending JP2020195401A (ja) | 2015-05-18 | 2020-08-31 | クッシング症候群についての処置を診断および評価するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10604807B2 (enExample) |
| EP (1) | EP3297728A4 (enExample) |
| JP (3) | JP6755264B2 (enExample) |
| KR (2) | KR20180008627A (enExample) |
| AU (1) | AU2016264321B2 (enExample) |
| CA (1) | CA2984623C (enExample) |
| IL (2) | IL309712A (enExample) |
| MX (1) | MX2017014857A (enExample) |
| PH (1) | PH12017502099B1 (enExample) |
| WO (1) | WO2016187347A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195214B2 (en) | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
| CN108389135A (zh) * | 2018-03-21 | 2018-08-10 | 安徽理工大学 | 一种基于灰色关联模型的突水水源判别方法 |
| CN113194957A (zh) * | 2018-12-21 | 2021-07-30 | 科塞普特治疗公司 | 通过施用糖皮质激素受体调节剂治疗库欣综合征中的高凝血病 |
| EP4157276A4 (en) | 2020-05-27 | 2024-06-12 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 |
| EP4157275A4 (en) * | 2020-05-27 | 2024-06-05 | Corcept Therapeutics Incorporated | CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C8 SUBSTRATES |
| MX2022014923A (es) * | 2020-05-27 | 2023-01-04 | Corcept Therapeutics Inc | Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU747956B2 (en) * | 1997-10-06 | 2002-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| JP2004526425A (ja) * | 2000-11-28 | 2004-09-02 | ワイス | 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析 |
| EP1616026A1 (en) * | 2003-04-14 | 2006-01-18 | Novartis AG | Gene expression associated with osteoblast differentiation |
| CA2736626C (en) * | 2008-09-12 | 2022-12-06 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Genes associated with posttraumatic-stress disorder (ptsd) |
| US8940705B2 (en) * | 2009-01-09 | 2015-01-27 | The Regents Of The University Of California | Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone |
| WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| JP2013090761A (ja) | 2011-10-25 | 2013-05-16 | Osaka City Univ | 立体視内視鏡装置 |
| NZ701469A (en) | 2012-05-25 | 2017-06-30 | Corcept Therapeutics Inc | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US20140170768A1 (en) | 2012-12-14 | 2014-06-19 | Joel R. L. Ehrenkranz | Method for monitoring and assessing pituitary function |
-
2016
- 2016-05-18 US US15/570,710 patent/US10604807B2/en active Active
- 2016-05-18 KR KR1020177035970A patent/KR20180008627A/ko not_active Ceased
- 2016-05-18 JP JP2017559803A patent/JP6755264B2/ja active Active
- 2016-05-18 KR KR1020247001601A patent/KR102876869B1/ko active Active
- 2016-05-18 EP EP16797242.1A patent/EP3297728A4/en not_active Withdrawn
- 2016-05-18 PH PH1/2017/502099A patent/PH12017502099B1/en unknown
- 2016-05-18 IL IL309712A patent/IL309712A/en unknown
- 2016-05-18 CA CA2984623A patent/CA2984623C/en active Active
- 2016-05-18 AU AU2016264321A patent/AU2016264321B2/en active Active
- 2016-05-18 WO PCT/US2016/033143 patent/WO2016187347A1/en not_active Ceased
- 2016-05-18 MX MX2017014857A patent/MX2017014857A/es unknown
-
2017
- 2017-11-12 IL IL255612A patent/IL255612A/en unknown
- 2017-12-12 US US15/839,666 patent/US11268145B2/en active Active
-
2020
- 2020-02-18 JP JP2020024990A patent/JP6893264B2/ja active Active
- 2020-03-19 US US16/823,802 patent/US20200216905A1/en not_active Abandoned
- 2020-08-31 JP JP2020145512A patent/JP2020195401A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miller et al. | Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma | |
| Lei et al. | Mitogen-activated protein kinase signal transduction in solid tumors | |
| Gao et al. | Interleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes | |
| JP2012529021A5 (enExample) | ||
| JP2020079799A5 (enExample) | ||
| Solomon et al. | Neuroendocrine factors and head and neck squamous cell carcinoma: An affair to remember | |
| Chen et al. | Retracted: microRNA‐145‐3p inhibits non‐small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway | |
| Budiu et al. | Restraint and social isolation stressors differentially regulate adaptive immunity and tumor angiogenesis in a breast cancer mouse model | |
| López-Alonso et al. | Impairment of autophagy decreases ventilator-induced lung injury by blockade of the NF-κB pathway | |
| NZ737362A (en) | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations | |
| Kawao et al. | Roles of the vestibular system in obesity and impaired glucose metabolism in high-fat diet-fed mice | |
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| Wen et al. | Electroacupuncture prevents white adipose tissue inflammation through modulation of hypoxia-inducible factors-1α-dependent pathway in obese mice | |
| Li et al. | Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model | |
| Miller et al. | Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis | |
| Fang et al. | Carnosol prevents cardiac remodeling and ventricular arrhythmias in pressure overload‐induced heart failure mice | |
| Bagheri et al. | Preoperative plasma MiRNA levels predict prognosis in Early-stage malignant melanoma | |
| Tseng et al. | A novel somatic mutation of CACNA1H p. V1937M in unilateral primary hyperaldosteronism | |
| Zhang et al. | Restoring the secretory function of irradiation-damaged salivary gland by administrating deferoxamine in mice | |
| Bossola et al. | Skeletal muscle in cancer cachexia: the ideal target of drug therapy | |
| Walker et al. | Central nervous system tumors | |
| Ding et al. | Altered expression of mRNA for HIF‐1α and its target genes RTP801and VEGF in patients with oral lichen planus | |
| Ferreira et al. | The impact of exercise training on adipose tissue remodelling in cancer cachexia | |
| Tao et al. | P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption | |
| Benbenishty et al. | Intraarterial anti-leptin therapy via ICA protects ipsilateral CA1 neurons subjected to ischemia and reperfusion |